Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27396768 | 0.83 | GABRA1 (0.39) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| SCHEMBL24022546 | 0.79 | GABRA1 (0.52) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| SCHEMBL21348074 | 0.79 | GABRA1 (0.35) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| SCHEMBL21367389 | 0.79 | GABRA1 (0.35) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| SCHEMBL23685898 | 0.79 | SIGMAR1 (0.37) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| SCHEMBL134760 | 0.78 | GABRA1 (0.46) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| SCHEMBL8755372 | 0.75 | GABRA1 (0.48) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| SCHEMBL4398016 | 0.75 | GABRA1 (0.48) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| SCHEMBL16919083 | 0.75 | GABRA1 (0.48) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| SCHEMBL24835479 | 0.75 | GABRA1 (0.35) | GABRA1GABRG2GABRB3GABRB2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076021-A1 | EMITTER MATERIAL FOR OLEDS | UNIV DORTMUND TECH (DE) | 2026-03-12 | — | — | US | disclosed |
| EP-4581037-A1 | EMITTER MATERIAL FOR OLEDS | Technische Universität Dortmund (DE) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024046539-A1 | EMITTER MATERIAL FOR OLEDS | TECHNISCHE UNIVERSITÄT DORTMUND (DE) | 2024-03-07 | — | — | WO | disclosed |
| CN-114031519-A | Method for synthesizing N-aryl imine | 浙江工业大学 | 2022-02-11 | — | — | CN | disclosed |
| WO-2021219999-A1 | AUTOMATED CHEMICAL SYNTHESIS PLATFORM | THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) | 2021-11-04 | — | — | WO | disclosed |
| WO-2016170328-A1 | TUNGSTEN CATALYSTS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2016-10-27 | — | — | WO | disclosed |
| EP-2311112-B1 | ELECTRONIC DEVICES COMPRISING METAL COMPLEXES HAVING ISONITRILE LIGANDS | MERCK PATENT GMBH (DE) | 2012-03-14 | — | — | EP | disclosed |
| US-20110101327-A1 | Electronic Devices Comprising Metal Complexes Having Isonitrile Ligands | MERCK PATENT GMBH (DE) | 2011-05-05 | — | — | US | disclosed |
| WO-2010015307-A1 | ELECTRONIC DEVICES COMPRISING METAL COMPLEXES HAVING ISONITRILE LIGANDS | MERCK PATENT GMBH (DE) | 2010-02-11 | — | — | WO | disclosed |
| US-7612245-B2 | converting 1,3-butadiene to cis-2-butene in presence of a hydrogenation catalyst mixture containing iron octanoate, triethylaluminium, 2,3-bis(2,6-dimethylphenylimino)butane; catalyst selectivity | INSTITUT FRANCAIS DU PETROLE (FR) | 2009-11-03 | — | — | US | disclosed |
| US-20070082918-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS AND COMPOUNDS WITH MULTIPLE ACTIVITIES | NAFTCHI N E | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110101327-A1 | Electronic Devices Comprising Metal Complexes Having Isonitrile Ligands | EXOC4, ICMT, NCLN | GABRA1 1035/4885GABRG2 902/4885GABRB3 870/4885 |
| US-20070082918-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS AND COMPOUNDS WITH MULTIPLE ACTIVITIES | ADRB2, ADRB1, CHRNA7 | GABRA1 41/4885GABRG2 74/4885GABRB3 24/4885 |
| US-20260076021-A1 | EMITTER MATERIAL FOR OLEDS | NR1H2, NR1H3, CNR1 | GABRA1 3528/4885GABRG2 3456/4885GABRB3 2959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.